Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Justthefacts you said ""Unfortunately that's how most buyers of CLBS get trapped, it's a bait and switch tactic, an illusion if you will. Oldest trick in the book, but then again, it's how people make (and lose) money in the stock market""
I am just curious about your remark?? How did CLBS bait you and I would really like to know what kind of switch tactic did they use?? Some how I guess I missed this!
Caladrius Biosciences: Teaching immune systems how to recognise and fight cancer Tuesday, June 30th, 2015
Need to read and watch this::: http://www.theneweconomy.com/technology/caladrius-biosciences-teaching-immune-systems-how-to-recognise-and-fight-cancer
To everyone out there! Lets respect everyone's opinion! We do not need to agree with anyone and are free to post all our thoughts BUT this is a adult board and name calling or abuse is bad for everyone!
Thank You 3 day trader! I for one appreciate your posts! I am not good at charts.
If you go here:: http://www.slideshare.net/Neostem/neostem-investor-presentation
You will see the June presentation of CLBS! If you to page 20 it starts to tell you about CLBS10 ALL THE WAY TO PAGE 28.
On page 27 it explains the time line for CLBS 10 as it stands now! This can change at anytime with a partnership!
I hope with the new board things get rolling soon! This board I hope will be able to define the endpoints as we move on! Here is a article about what is happening in Japan that will be to our advantage compared to what is happening here! Hopefully that partnerships will not be that far off!
http://replicel.com/recent_coverage/japans-take-on-regenerative-medicine-early-commercialization-early-reimbursement/
I know it was only a penny up but it was the only green stock I had today, LOL OMG NVIV joined the Russell Global, Russell 3000, Russell 2000, and Russell Microcap Indexes today and that usually is a real good thing! It dropped $2.25 a share then GILD got hammered at $4.04 I think a share then the all the others I have went down also!
S&P 500
2,057.64
-43.85 (2.09%)
Dow
17,596.35
-350.33 (1.95%)
Nasdaq
4,958.47
-122.04 (2.40%
WE ARE SO LUCKY TODAY>>>LOL
The only thing I hate is in his first line it says::
Summary
•Negative results from AMR-001 have already been priced into the stock.
Hello there where no negative results!
People see this and stand back without reading the rest!
As you say about the paragraph::
Atorvastatin, or Lipitor, the best-ever selling drug, which has over $115 billion in sales over about 15 years can improve LVEF by about 2.5% in 6 months and about 6% over 3 years. NBS10, however, when dosed at 20 million CD34+ or higher has been effective at improving a patient's LVEF about 10.2% in as little as 6 months, and one can only assume it could increase even further in the one-year results being presented March 15. This is a significant breakthrough for NeoStem, because this shows that the CD34+ cells are effectively healing the heart and improving the function of the heart.
The problem is the first line stopped a lot from reading further! Yes I think everybody should read it all BUT we all now that does not happen!!
We where beyond this when AF wrote the article! The endpoints had been changed before this article or I should say smear article was written! We know that it depends on the number of cells injected that determines the outcome! I think that is why they got the panel of doctors together to help form the next phase!
I agree with you BUT the results where blown out of proportion by that idiot AF! The endpoint was discussed by the FDA and NBS and was changed BEFORE the results where even released! In trials this is not unusual at all, even the big pharms do changes in the trial! The FDA does no usually use the imaging as result for endpoints. Adam Furstien(I think that is his name from the street) Declared at the release of the result that NBS had changed the endpoint to suit the results which was not true and continued a campaign to make the results a joke even after cardiologist proclaimed the results where really good! The endpoint of MACE (major adverse cardiac events) is how the FDA wanted it measured and it passed really easy on those terms!
I far as I know all results have been very good so far! The completion date is listed as December 16th. That could change or they could get fast tracked. Here is the page on clinical trials for CLBS10 https://clinicaltrials.gov/ct2/show/NCT01495364
You can also see the resuts so far
PreSERVE 6- and 12-month Interim Conclusions*
•CD34 cell dose-dependent trend in reduced major adverse cardiac events (MACE)
•Reduced serious adverse events (SAEs) frequency trend in higher CD34 cell dose groups (12 month data)
•No deaths in the CLBS10 treated group (12 month data)
•CD34 cell dose-dependent trend in improved left ventricular ejection fraction (LVEF) and in reduced infarct size
•No correlation between experimental endpoint of perfusion and treatment
* Based on data collected at 6 months except where noted
Taken together, these preliminary results suggest that CLBS10 positively impacts the preservation of myocardial function and the prevention of adverse events post-STEMI. The favorable clinical outcomes encourage continued development. For more details, please visit the trial's listing on clinicaltrials.gov.
Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board to Support Ongoing Development Efforts Using CD34 Cells
NEW YORK, June 29, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. ("Caladrius" or "the Company") (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology—as well as earlier-stage development programs in ischemic repair (based on CD34 cells) and autoimmune disease (based on T regulatory cells)—announced today its establishment of a cardiovascular disease scientific advisory board. The board consists of internationally renowned experts in cardiology, including esteemed professors of cardiology, research directors and department chairs, and will advise and provide support to Caladrius in the areas of cardiology research and clinical development.
The members of the advisory board include:
•Robert Harrington, MD, Arthur L. Bloomfield Professor of Medicine, Chair, Department of Medicine, Stanford University, Stanford, California
•Timothy Henry, MD, Chief of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, California
•Thomas Povsic, MD, PhD, Associate Professor of Medicine, Duke Clinical Research Institute, Durham, North Carolina
• Arshed Quyyumi, MD, FACC, FRCP, Professor of Medicine, Co-Director, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia
•Richard Schatz, MD, Research Director, Cardiovascular Interventions, Director, Gene & Cell Therapy, Scripps Clinic, La Jolla, California
•Christopher White, MD, MSCAI, FACC, FAHA, FESC, Professor and Chairman of Medicine, Ochsner Clinical School and Chief of Medical Services, Ochsner Medical Center, New Orleans., Louisiana
•Joseph C. Wu, MD, PhD, Director, Stanford Cardiovascular Institute, Professor, Department of Medicine (Cardiology) & Radiology, Stanford University, Stanford, California
•Andreas Zeiher, MD, Professor of Medicine, Chairman, Department of medicine, Goethe University, Frankfurt, Germany
"This impressive group of physicians and researchers dedicated to cardiac health will offer valuable input to Caladrius as we determine the next development steps for our ischemic repair program based on CD34 cell technology," said Dr. David J. Mazzo, Chief Executive Officer of Caladrius Biosciences.
Caladrius Biosciences has completed a Phase 2 study of its investigational therapy CLBS10 for ischemic repair in patients with ST Segment Elevation Myocardial Infarction (STEMI). The technology platform on which this study was based is potentially applicable across indications including congestive heart failure, critical limb ischemia, intermittent claudication and stroke.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
CONTACT: Caladrius Biosciences, Inc.Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Read more: http://www.nasdaq.com/press-release/caladrius-biosciences-establishes-cardiovascular-scientific-advisory-board-to-support-ongoing-20150629-00200#ixzz3eRyFCDqh
Did anybody notice the after-hours activity on Friday? There was 1,500,032 after-hours! One lot alone was 962,139?????? http://www.nasdaq.com/symbol/clbs/after-hours
OMG do not go there! I have not even thought of that! I really do not know how far down I will go, been in it 3 years and have constantly added! I truly believe in the science and the company or would not have stuck in it this long!
I got to much in it to sell! I honestly believe this will make me rich someday! I hope you are not walking down the street one day and see me sitting with a tin can by my side! If so throw a quarter in! ROFLMAO
I just love that title also Lynx5100 >>>Biotech Stocks for your portfolio! Really nice find Lynx5100 ! I hope the news keeps getting out!
Thanks for the post, very informing! Yes the CLBS20 treatment blows the others away in results! Hopefully sooner than later people will start to realize this! This stock is worthy every cent spent BUT needs to start a up trend@!
It is amazing they did not mention CLBS at all! Most those pharms deal with PCT!!
Using your own tumor to fight skin cancer
June 24, 2015 / kmccormack2014
Some things never get old. Like watching the sunset over the Grand Canyon. Listening to a baby laugh. Watching the San Francisco Giants win the baseball World Series. Now you can add to that list learning that one of the clinical trials we are funding has just treated their first patient.
The latest to join that growing list is Caladrius Biosciences (previously called NeoStem). We recently awarded them $17.7 million to carry out a Phase 3 metastatic melanoma clinical trial targeting cancer stem cells. These cells are believed to be able to survive chemotherapy and other cancer-targeting treatments, and can cause a relapse by enabling tumors to grow and spread.
Caladrius’ approach is a personalized one. They use the patient’s own tumor cells to create a therapeutic vaccine called (for now at least) CLBS20. It’s designed to engage the patient’s own immune system and destroy the cancer.
This first patient was treated at Thomas Jefferson University Hospital in Philadelphia. Altogether Caladrius hopes to enroll some 250 patients at more than 40 sites worldwide, for the trial. Seven of those sites are here in California; that’s the portion of the project we are funding.
Because this is a randomized, double blind study it’s not known if the patient was treated with CLBS20 or a placebo. But in a news release Dr. David J. Mazzo, CEO of Caladrius Biosciences, says it’s a big first step:
“The dosing of the first patient in this Phase 3 trial is an important milestone for our Company and the timing underscores our focus on this program and our commitment to impeccable trial execution. We are delighted by the enthusiasm and productivity of the team at Jefferson University and other trial sites around the country and look forward to translating that into optimized patient enrollment and a rapid completion of the Phase 3 trial.”
In the earlier Phase 2 trial, 72 percent of those who got the therapy were still alive after two years, compared to 31 percent of people who got a placebo therapy. There was another bonus for patients; the treatment was well-tolerated with few side effects, the most common being irritation and a reaction at the site of the injection.
There’s a big need for this approach. In 2014 there were approximately 20,000 new cases of metastatic melanoma and nearly 10,000 deaths. It usually causes death within one to two years and only 10 to 15 percent of patients survive five years.
Here’s where to go if you would like more information on the Intus Study or you can also visit the NIH clinical trials site.
http://blog.cirm.ca.gov/2015/06/24/using-your-own-tumor-to-fight-skin-cancer/
Thank You!
It is like the World Series, we all know it will be played BUT it is not official till the first ball is thrown!
Yes we are official!! Yeah and I agree also with Flash this may be the kick we needed!!
Congrats and Good Luck to the first patient! I hope you do really well and are cured!
PRE-market>>>>$2.09 up 6.09%
Caladrius Biosciences, Inc. (CLBS) Pre-Market Trading
CLBS
$2.09
*
0.12
6.09%
Get CLBS Alerts
*Delayed - data as of 06/23/2015 07:33 - Find a broker to begin trading CLBS now
Read more: http://www.nasdaq.com/symbol/clbs/premarket#ixzz3dswKbsXb
Caladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma
Clinical Milestone for Immuno-Oncology Therapy That Works by Turning Cancer Against Itself
New York, June 22, 2015 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today the dosing of the first patient in the Intus Phase 3 clinical trial. The Intus trial is investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate CLBS20 (also known as NBS20). The trial is studying CLBS20 in patients with stage III recurrent or stage IV metastatic melanoma.
The patient was dosed (with either CLBS20 or control, in accordance with the randomized, double-blind design of the study) at the clinical trial site at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. The announcement comes on the heels of a $17.7 million grant from the California Institute for Regenerative Medicine awarded to help fund the trial.
"We are excited to be a part of the Intus study and to contribute to the advancement of this and any potentially life-prolonging investigational therapy," said Dr. Takami Sato, principal investigator for this site and Professor of Medical Oncology at Thomas Jefferson University.
The Intus trial is based on consistent, compelling results from two Phase 2 trials in identical patient populations evaluating the therapeutic vaccine that has become CLBS20. The more recent of the two trials was a randomized trial comparing CLBS20 to injections of autologous irradiated (inactivated) tumor cells in 42 patients. At two years, survival was 72% compared to 31% for control patients, which was consistent with the previous Phase 2 trial's findings in which CLBS20 demonstrated 73% two-year survival in 54 patients, with a median survival of five years. Treatments were well-tolerated; the most common side effects were mild to moderate local injections site reactions.
CLBS20 is an individualized therapy developed for each patient from that patient's own tumor and immune cells. It works by combining certain irradiated tumor cells (those thought to be the cancer-initiating cells responsible for tumor proliferation) with the patient's immune cells, called dendritic cells. The cell-based product is then admixed with an immune adjuvant that stimulates white blood cells and injected into the patient, essentially turning the cancer against itself.
Potential patients for the trial are pre-screened based on the trial's eligibility criteria, and tumor tissue samples are collected and delivered to the Caladrius manufacturing facility. Once tumor cell lines have been successfully established, each patient is screened for enrollment and is randomized into either treatment or control. The second part of CLBS20 manufacture requires collection of specific immune cells from that patient using a standard blood collection technique, and manufacture of the final product from the immune cells and tumor cells, which takes one month. The product is shipped to the treating location, and at the time of treatment, the product is thawed for injection and admixed with an immune adjuvant. The patient then receives the therapy via subcutaneous injections once a week for three weeks and then once a month for five months.
In addition to metastatic melanoma, the technology platform on which CLBS20 is based is potentially applicable across lung, colon, renal and ovarian cancers, hepatocellular carcinoma and glioblastoma multiforme-indications that collectively lead to more than 200,000 deaths in the United States each year.
"The dosing of the first patient in this Phase 3 trial is an important milestone for our Company and the timing underscores our focus on this program and our commitment to impeccable trial execution," said Dr. David J. Mazzo, Chief Executive Officer of Caladrius Biosciences. "We are delighted by the enthusiasm and productivity of the team at Jefferson University and other trial sites around the country and look forward to translating that into optimized patient enrollment and a rapid completion of the Phase 3 trial."
For more information on the Intus Study please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.
About Metastatic Melanoma
Melanoma is the most lethal form of skin cancer. Patients who have progressed to stage IV melanoma have a cancer that has metastasized-or spread-to distant sites in the body such as the lymph nodes, lungs, liver or brain. As a result, advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases of, and an estimated 10,000 deaths from, metastatic melanoma each year in the United States. Treatments for stage IV melanoma are typically directed at slowing the growth of the cancer and prolonging survival. Current treatment options include radiation, chemotherapy, surgical resection, immunotherapy, or a combination approach. Unfortunately, current therapies have had limited impact on long-term survival for most patients. Even with the newer targeted therapies (anti-checkpoint inhibitors and specific enzyme inhibitors), half of patients with metastatic melanoma still die within 13 to 17 months from the start of such treatment. Administering certain anti-melanoma drugs at higher doses or in combinations may be more effective, but often results in more severe side effects.
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
New event happening tomorrow!
International Society for Stem Cell Research Annual Meeting
Jun 24, 2015
8:40 AM WEDT
http://www.isscr.org/home/annual-meeting/isscr2015
Stockholmsmässan Exhibition and Convention Center, Stockholm, Sweden Dr. Hans Keirstead will present on “Development of an Immune Based Therapy for Melanoma”.
http://www.caladrius.com/event/international-society-for-stem-cell-research-annual-meeting/
Please, I am sorry if I offended anybody with my remarks, I am very sorry for your lose. It was not made to hurt anybody and we all have had loses in one way or another. I think the subject should be dropped, there is no need to continue the conversation on who is right or who is wrong. Again I am very sorry for your lose!
Here you can check my post from May 10th from this board! post 1780 I always thank both because it is very hard raising children and answering there questions if you are a single parent! I am also so proud of the men that now step up and take this on! It is hard no matter who you are!
Viperciara Sunday, 05/10/15 09:52:46 AM
Re: None
Post #1780 of 2101
Happy Mothers day to all the Women and men who take care of there children!
Happy Fathers day to all the men of the world and women who have had both jobs!
Sorry to say this but I am praying right now it goes no lower!! The for sale sign is down!
I in know way believe it is a scam! This company has been around for years and has some of the world leading doctors in its field! It is being manipulated either by shorts or somebody trying to put them out of business, who knows> This is why I posted months and weeks ago how the PPS was doing. Every time good news comes out the PPS drops. Do you think the FDA would fast track a SCAM??LOL These trials have been going on since 2009! Do you think major companies would be buying PCT service for there trails if it was a scam??
I do not think anybody other than yourself should be the judge of where you get out at! It is hard to say what is going on? I am at my wits end myself and I have a much higher PPS than you! I keep buying so I lowered my PPS from $6 something down to $3 and now the PPS is so low on the stock it is ridiculous! Every time we have good news it goes down?? Somebody is manipulating the stock very bad!
I have contacted them numerous times! Eric Powers seems to be the one that answers>>>But no not all my emails have been answered!
Article from June 9th>>I had not seen the article before so posting now, I did like this statement from the article!
Mazzo said,
“Given that we acquired this asset approximately one year ago and, in the ensuing months, much of the external focus on our company was on our ischemic repair Phase 2 program, we believe that the market has not yet integrated the full potential of this mature immuno-therapy asset into the value of our company.”
To read full article go here>>>> http://californiastemcellreport.blogspot.com/2015/06/neostems-new-name-backed-by-29-million.html
It is hard to understand how they do not PR there products BUT this new management is doing a little better! I do not understand how I can find articles about them that are great and they never even acknowledge them?? Remember voting is coming up and that is for the bonuses also! Sometimes hitting somebody in the pocket helps but sometimes they get up and leave to another company also! I have to admit there line-up they have now are all well know great people and I would hate to lose them. THEY NEED A GOOD PR PERSON! They I feel should have that webcast up on there sight already so people who missed it can view it BUT it is not there?
This might still work. You have to make a account to listen. I checked they usually have one on the website but can not find it yet! http://www.caladrius.com/event/2015-bio-international-convention/
Here is a idea of what some companies have gone threw!
THIS IS NOT CLBS but a idea of some of the problems stem cell companies have!
http://californiastemcellreport.blogspot.com/2015/06/the-hard-business-of-stem-cell.html
Monday, June 15, 2015
California Hits Its Mark on Faster Delivery of Cash for Stem Cell Research
•Caladrius to get first installment on nearly $18 million
•Agency President Randy Mills Pleased with CIRM 2.0 Overhaul
SAN FRANCISCO -- The California stem cell agency may not be faster than a speeding bullet, but it is running way more quickly than it was a year ago.
For researchers and patients, that means the agency’s millions are moving more rapidly into development of therapies and cures with the goal of beginning to save lives sooner rather than later.
The signal event came last week when the agency, formally known as the California Institute for Regenerative Medicine(CIRM), signed off on a contract with Caladrius Biosciences, Inc., of New York.
As soon as Caladrius signs the agreement, it will receive a check for $3 million, the first installment on a nearly $18 million award that was approved by directors less than a month ago.
Randy Mills
CIRM President Randy Mills was delighted last Friday when he told the California Stem Cell Report about the action on the Caladrius award. (Caladrius was formerly known as NeoStem.)
Mills, who has been head of the agency for only a little over a year, mentioned the news during a 45-minute conversation in his office at CIRM headquarters.
It was the first award paid out under Mills’ new, CIRM 2.0 program, an effort designed to speed cash to researchers and improve the quality of applications. It is also the first CIRM award in a stage three trial, the last step in the process of winning government approval for widespread public use of a therapy.
The agency approved the actual Caladrius contract last Thursday, 21 days after the directors’ approval. Mills’ goal was to act on the contract within 45 days.
CIRM’s 2.0 clock shows Caladrius’ application for the melanoma therapy coming in at the end of February, 113 days ago. Mills’ goal is to have action completed on an application within 120 days from the time it officially enters the 2.0 system -- instead of up to two years as in the past.
The firm offered its initial application at the end of January, but it was sent back for improvement.
Next up in the first round of CIRM 2.0 awards is final action on a $5 million award to Shaomei Wang of Cedars-Sinai that was also approved on May 21 by CIRM directors.
Mills said last Friday that CIRM 2.0 has not been perfect and that in some cases implementation required "brute force." But he is pleased overall. Later this year, Mills and his team plan to apply CIRM 2.0 to basic and translational awards, all of which will mean significant changes for hundreds of California scientists.
Sphere: Related Content
Posted by David Jensen at 3:08 PM ShareThis
Labels: caladrius, cirm 2.0, grant making, mills, neostem
Let me think about that one LOL I will let you know in a couple days ok?